Find your perfect fit.

Great companies are being built by amazing teams. Come be a part of it.
101
companies
1,275
Jobs
At Menlo Ventures, we invest in companies that will change how we live and work. To do that, they need creative thinkers, problem solvers, builders, and business leaders. They look to Menlo for help building their teams.
Tell us more about your professional DNA to get discovered by the companies we back.
Pliant Therapeutics
Pliant Therapeutics
pliantrx.com

Locations

South San Francisco, CA, USA

industry

Biotechnology · DeepTech · Health · HR and Recruiting · Professional Services

Size

51-200 employees

Stage

Other

founded in

2015

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.


Is this your company?

If you're responsible for hiring at this company, make sure your company and job information are always up to date to attract top talent from the Menlo Ventures network.

Something looks off?
Open jobs at Pliant Therapeutics
Powered by Getro